|
|
Blood, 1 March 2008, Vol. 111, No. 5, pp. 2785-2789.
Prepublished online as a Blood First Edition Paper on November 15, 2007; DOI 10.1182/blood-2007-06-095703.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders
Animesh Pardanani1,
Brooke L. Fridley2,
Terra L. Lasho1,
D. Gary Gilliland3,4, and
Ayalew Tefferi1
Divisions of1 Hematology and
2 Biostatistics, Mayo Clinic, Rochester, MN;
3 Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and
4 Howard Hughes Medical Institute, Harvard Medical School, Boston, MA
JAK2V617F is an acquired mutation associated with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). We tested the hypothesis that the paradox of a single disease allele associated with 3 distinctive clinical phenotypes could be explained in part by host-modifying influences. We screened for genetic variation within 4 candidate genes involved in JAK-STAT signaling, including receptors for erythropoietin (EPOR), thrombopoietin (MPL), and granulocyte colony-stimulating factor (GCSFR), and JAK2. We genotyped 32 linkage disequilibrium tag single nucleotide polymorphism (SNP) loci in 179 white patients: 84 had PV, 58 had PMF, and 37 had ET. Genotype-phenotype analysis showed 3 JAK2 SNPs (rs7046736, rs10815148, and rs12342421) to be significantly but reciprocally associated with PV (P < .001 for all; odds ratio = 0.16, 2.72, and 2.46, respectively) and ET (P < .001 for all; odds ratio = 3.05, 0.29, and 0.30, respectively) but not with PMF. Three additional JAK2 SNPs (rs10758669, rs3808850, and rs10974947) and a single EPOR SNP (rs318699) were also significantly associated with PV but not with ET or PMF. Finally, intragene haplotypes in JAK2 were significantly associated with PV only. Thus, host genetic variation may contribute to phenotypic diversity among myeloproliferative disorders, including in the presence of a shared disease allele.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
JAK2: how many faces in MPDs?
- Alessandro M. Vannucchi
Blood 2008 111: 2499.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
A. M. Vannucchi, G. Masala, E. Antonioli, M. Chiara Susini, P. Guglielmelli, L. Pieri, L. Maggi, S. Caini, D. Palli, C. Bogani, et al.
Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
Cancer Epidemiol. Biomarkers Prev.,
July 1, 2009;
18(7):
2068 - 2073.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Vannucchi, P. Guglielmelli, and A. Tefferi
Advances in Understanding and Management of Myeloproliferative Neoplasms
CA Cancer J Clin,
May 1, 2009;
59(3):
171 - 191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Passamonti and E. Rumi
Clinical relevance of JAK2 (V617F) mutant allele burden
Haematologica,
January 1, 2009;
94(1):
7 - 10.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Van Pelt, F. Nollet, D. Selleslag, L. Knoops, S. N. Constantinescu, A. Criel, and J. Billiet
The JAK2V617F mutation can occur in a hematopoietic stem cell that exhibits no proliferative advantage: a case of human allogeneic transplantation
Blood,
August 1, 2008;
112(3):
921 - 922.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Vannucchi and P. Guglielmelli
Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations
Haematologica,
July 1, 2008;
93(7):
972 - 976.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Levine
JAK2V617F: you can't have too much
Blood,
April 15, 2008;
111(8):
3913 - 3913.
[Full Text]
[PDF]
|
|
|
|
|
